| News
The DayOne Accelerator, in its 3rd year, is now accepting applications
02.10.2020
We are excited to announce the opening of the call for the DayOne Accelerator, now in its 3rd year!
If you are a digital health entrepreneur that wants to gain feedback on your innovation, build connections across the healthcare ecosystem and potentially win a place in the DayOne Accelerator, then you are in the right place. The accelerator will again help you to develop your digital health venture together with one of Europe’s leading ecosystems with coaching, space and potential funding. The first step to send in your application before the 23.10.20 deadline. We will let you know by 05.11.2020 whether you are shortlisted for the accelerator program and therefore invited to in the DayOne Open Innovation Session
This year the accelerator will have three categories: Patient Centric Innovation, Diabetes & Metabolism, and Value Based Healthcare. For more information about the categories, full list of winner benefits, list of previous winners and more, visit the DayOne Accelerator page.
Don’t forget to apply before the 23.10.20 deadline, and feel free to send those in your network who could also be interested in participating; after all, we do love collaboration at DayOne.

Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
Ground-breaking oncology being developed in the Basel Area
The Basel Area – covering northwestern Switzerland – has seen tremendous growth in recent years, and has become a true...
Read MoreGenedata expanding its user network
The Japanese biopharmaceutical firm Ajinomoto is to use the Genedata solution to accelerate its drug development processes at its site...
Read MoreHow Moderna is growing in Switzerland
The number one rule in real estate is “Location, Location, Location.” The global biotech company Moderna found its location in...
Read MoreSandoz decides on Basel for headquarters
Sandoz AG will continue to have its headquarters in Basel as an independent company. The separation from Novartis is expected...
Read MoreVectivBio sold for approximately 1 billion dollars
The takeover of VectivBio is now being finalized: the Boston-based firm Ironwood Pharmaceuticals, which specializes in gastrointestinal medicine, has agreed...
Read MoreUniversity of Basel and RocketVax present new Covid vaccine
Researchers from the University of Basel have developed a new concept for a Covid vaccine in collaboration with the biotech...
Read More